vVARDIS Founders Present Drill-Free Early Cavity Treatment and Unveil Global Cavity Awareness Campaign at the 2026 J.P. Morgan Healthcare Conference

EQS-Media / 12.01.2026 / 18:35 CET/CEST FOR IMMEDIATE RELEASE vVARDIS Founders Present Drill-Free Early Cavity Treatment and Unveil Global Cavity Awareness Campaign at the 2026 J.P. Morgan Healthcare Conference

vVARDIS founders Drs. Haley and Goly Abivardi share details on oral healthcare company’s remarkable growth trajectory – with over 2 million teeth treated in 24 months – at premiere healthcare investment event

SAN FRANCISCO, CA – January 12, 2026 – vVARDIS, a Swiss high-growth healthcare company, active in the development of innovative dental products, today presented its pioneering solution for the treatment of early cavities, Curodont, at the 2026 J.P. Morgan Healthcare Conference. Founded by dentist-entrepreneur sisters Drs. Haley and Goly Abivardi, vVARDIS is recognized for its commitment to advancing the standard of non-invasive dental care through Curodont, its drill-free solution for dental professionals. The product has experienced rapid growth and attracted significant investor attention since its launch in the U.S. market two years ago.

The vVARDIS founders returned to the conference stage after being personally highlighted by J.P. Morgan CEO Jamie Dimon at the 2025 event— rare in the conference’s history. This recognition highlights vVARDIS' status as an innovative, disruptive and rapidly growing company in the dental sector.

“Being recognized by Jamie Dimon and invited to return as presenters at the J.P. Morgan Healthcare Conference is an extraordinary honor—not just for us, but for the entire field of oral health,” said Dr. Haley Abivardi, DMD, co-CEO and co-founder of vVARDIS. “This platform has amplified our ability to reach the world’s leading healthcare innovators and investors, accelerating our mission to transform how cavities are treated globally and improve overall health through better oral health.”

During their presentation at the conference, Drs. Haley and Goly Abivardi showcased vVARDIS as a company founded by dentists and serial dental entrepreneurs, dedicated to addressing the global burden of cavities as indicated by the World Health Organization. They highlighted that, prior to the launch of Curodont, dental professionals had no non-invasive restorative treatment option for early-stage cavities; drilling and filling was the only available approach. Curodont, vVARDIS' innovative flagship technology, offers significant benefits to both patients and dental professionals as a non-invasive, environmentally friendly solution for the treatment of early-stage cavities. At the presentation, they shared vVARDIS’ ongoing commercial momentum and strong growth metrics, including over 2 million teeth treated in the U.S. alone in 24 months[1]. The presentation underscored vVARDIS’ unique investment proposition, emphasizing the company’s access to a large and growing market, its breakthrough science and proven clinical results, and the significant commercial momentum achieved in recent years—making Curodont the fastest-growing dental product in its category in the U.S.[2].